



**For Immediate Release  
December 17, 2018**

## **Sunshine Biopharma Receives Health Canada Approval for Essential 9™, The Company's First Over The Counter Essential Micronutrient**

Montreal, Quebec, Canada – (ACCESSWIRE) – Sunshine Biopharma, Inc. (OTC Markets: "SBFM") today announced that it has received Health Canada approval for Essential 9™, the first in a line of essential micronutrients products that the Company is planning to launch. On Friday December 14, 2018, Health Canada issued NPN 80089663 through which it authorized Sunshine Biopharma to manufacture and sell the Essential 9™ product. Essential 9™ are dietary supplement tablets that contain a balanced formula of the 9 essential amino acids that the human body cannot make. Sunshine Biopharma anticipates to start shipping Essential 9™ in the second week of January 2019.

### **About Essential 9™**

Essential Amino Acids are 9 out of the 20 amino acids required for protein synthesis. Proteins are involved in all body functions – From the musculature and immune system to hormones and neurotransmitters. Like vitamins, Essential Amino Acids cannot be made by the human body and must be obtained through diet. Deficiency in one or more of the 9 Essential Amino Acids can lead to loss of muscle mass, fatigue, weight gain and reduced ability to build muscle mass in athletes. Sunshine Biopharma's Essential 9™ provides all 9 Essential Amino Acids in freeform and in the proportions recommended by Health Canada

### **Safe Harbor Forward-Looking Statements**

*To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, future collaboration agreements, the success of the Company's development, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made.*

### **For Additional Information: Sunshine Biopharma, Inc.**

Camille Sebaaly, CFO

Direct Line: 514-814-0464

[camille.sebaaly@sunshinebiopharma.com](mailto:camille.sebaaly@sunshinebiopharma.com)

[www.sunshinebiopharma.com](http://www.sunshinebiopharma.com)